Literature DB >> 31093717

[Renal cell carcinoma diagnosis and prognosis within the context of the WHO classification 2016].

A Zimpfer1, Ä Glass2, H Zettl3, M Maruschke4,5, O W Hakenberg5, A Erbersdobler6.   

Abstract

BACKGROUND: Histological classification of renal cell carcinoma (RCC) has become more and more important for clinical management, but relatively few is known regarding the swiftness with which the 2016 World Health Organization (WHO) classification of RCC was adopted in the daily routine diagnostics. AIM: To retrospectively review the histological diagnosis of RCC within the context of 2016 WHO classification followed by survival analysis.
MATERIAL AND METHODS: Retrospective register based analysis of RCC diagnosis between 1998 and 2017 and survival analysis.
RESULTS: 1440 RCC cases were registered between 1998 and 1917. According to 2016 WHO classification, 77.7% clear cell RCC and 22.3% non-clear cell RCC were diagnosed. A total of 37 rare subtypes were recorded, among those 1% MiT family translocation RCC, 0.35% acquired cystic disease-associated RCC, 0.35% multilocular cystic renal neoplasm of low malignant potential, 0.35% collecting duct carcinoma, 0.3% mucinous tubular and spindle cell carcinoma, 0.1% clear cell papillary RCC and 0.1% RCC with (angio)leiomyomatous stroma. Cox regression analysis showed significant different overall survival and progression-free survival between the histological subtypes. DISCUSSION: The complexity of the 2016 WHO classification of RCC put high demands on histopathological diagnostics. At University Medicine Center Rostock morphological distinct RCC entities have been mostly diagnosed by conventional means via hematoxillin and eosin stained slides, but beyond immunohistochemistry additionally molecular techniques were established. The histologic subtyping of RCC according to 2016 WHO classification has prognostic significance and might have predictive significance for unique therapeutic approaches.

Entities:  

Keywords:  2016 WHO classification; Histology; Prognosis; RCC subtyping; Renal cell carcinoma

Mesh:

Year:  2019        PMID: 31093717     DOI: 10.1007/s00120-019-0952-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  6 in total

1.  Performance of CT radiomics in predicting the overall survival of patients with stage III clear cell renal carcinoma after radical nephrectomy.

Authors:  Dong Han; Nan Yu; Yong Yu; Taiping He; Xiaoyi Duan
Journal:  Radiol Med       Date:  2022-07-14       Impact factor: 6.313

2.  Comparative study of CT and MRI appearances in mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma.

Authors:  Dajun Lu; Weibiao Yuan; Qingqiang Zhu; Jing Ye; Wenrong Zhu; Wenxin Chen
Journal:  Br J Radiol       Date:  2021-09-03       Impact factor: 3.629

3.  N6-methyladenosine methylation related immune biomarkers correlates with clinicopathological characteristics and prognosis in clear cell renal cell carcinoma.

Authors:  Zhilong Huang; Weiting Kang; Qi Zhang
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

4.  Diagnostic test accuracy of ADC values for identification of clear cell renal cell carcinoma: systematic review and meta-analysis.

Authors:  Mickael Tordjman; Rahul Mali; Guillaume Madelin; Vinay Prabhu; Stella K Kang
Journal:  Eur Radiol       Date:  2020-03-06       Impact factor: 5.315

Review 5.  Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review.

Authors:  Melissa Bersanelli; Matteo Brunelli; Letizia Gnetti; Umberto Maestroni; Sebastiano Buti
Journal:  Ther Adv Med Oncol       Date:  2020-05-26       Impact factor: 8.168

6.  Causal Associations between Serum Urea and Cancer: A Mendelian Randomization Study.

Authors:  Yandi Sun; Jingjia Li; Zihao Qu; Ze Yang; Xueyao Jia; Yindan Lin; Qian He; Lihong Zhang; Yan Luo
Journal:  Genes (Basel)       Date:  2021-03-29       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.